Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1323099 (sympathomimetic)
 2,957 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of 1-(4-hydroxyphenyl)-2-methylamin-propanol- (1) (oxilofrine, 4-HMP) on the catecholamine metabolism were investigated in vitro in isolated rat hearts and spleen sections. Investigations were conducted in vivo to determine the influence exerted by the sympathomimetic agent on the noradrenaline biosynthesis in the heart and on the oxygen-dependent enzymes tyrosine hy droxylase and dopamine-beta-hydroxylase. Oxilofrine is an excellent inhibitor of the noradrenaline storage in the heart (DI = 1.5 X 10(-6) mol/l). At the same time, the sympathomimetic agent releases noradrenaline from the storage compartments. In this process, preferably newly synthetised noradrenaline is released both from the heart and from the spleen. This double mechanism of action is associated with an acceleration of the noradrenaline biosynthesis and an increase in enzymal activity of tyrosine hydroxylase and dopamine-beta-hydroxylase. The transmitter concentrations in the region of the postsynaptic receptors are enhanced by oxilofrine.
 ...
PMID:[Effects of oxilofrine on the activity of the sympathetic nervous system (author's transl)]. 610 99

Experiments in vitro have shown 1-(4-hydroxyphenyl)-2-methylamino-propanol-(1) (oxilofrine, 4-HMP) to release noradrenaline from cardiac ventricular sections. This effect sets in at a concentration of 10(-5) mol/l and reaches the 30% level at 5X10(-5) mol/l. The inhibition of noradrenaline storage is still more pronounced. At 5 X 10(-5) mol/l the inhibition is 60%. The significance of both mechanisms of action of the sympathomimetic agent is discussed in comparison with compounds of related structure.
 ...
PMID:[Effects of oxilofrine on the release and storage of noradrenaline in cardiac sections of the rat (author's transl)]. 719 Dec 69